Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019

HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a
pharmaceutical company focused on the development and commercialization
of therapeutic and diagnostic technologies to tackle unmet medical
needs, announced today that the Company, in a privately-negotiated
transaction, repurchased all outstanding US$13,500,000 in aggregate
principal amount of the 8.00 per cent. convertible bonds due 2019
(“Convertible Bonds”) from Peace Range Limited, a wholly owned
subsidiary of Adamas Ping An Opportunities Fund LP, together with
certain subscription right to subscribe up to the principal amount of
the Bond at a US$12.17 (subject to adjustment) on or before December 17,
2019 (“Subscription Right”).

The total consideration of the repurchase of the Convertible Bonds and
the Subscription Right was US$13.6 million in cash, excluding accrued
interest. The repurchase of the Convertible Bonds and Subscription Right
was executed by Aptorum Investment Holding Limited, a wholly owned
subsidiary of Aptorum Group Limited. Pursuant to the repurchase, Aptorum
Group would not have any outstanding group liabilities in respect of the
Convertible Bonds or Subscription Right.

About Aptorum Group Limited

Aptorum is a pharmaceutical company dedicated to developing and
commercializing a broad range of therapeutic and diagnostic technologies
to tackle unmet medical needs. Aptorum is pursuing therapeutic and
diagnostic projects in neurology, infectious diseases, gastroenterology,
oncology and other disease areas; on the other hand, it also houses
projects focused on non-therapeutic areas such as surgical robotics as
well as the operations of its medical clinic in Hong Kong, Talem
Medical, with the initial focus on treatment of chronic diseases
resulting from modern sedentary lifestyles and aging population.

For more information about the Company, please visit www.aptorumgroup.com.

Forward-Looking Statements

This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose, any
statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum has based these forward-looking statements
largely on its current expectations and projections about future events
and trends that it believes may affect its business, financial condition
and results of operations.

These forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued service
and availability of key personnel, its ability to expand its product
assortments by offering additional products for additional consumer
segments, Aptorum Group Limited’s anticipated growth strategies,
anticipated trends and challenges in its business, and its expectations
regarding, and the stability of, its supply chain, and the risks. These
are disclosed in Aptorum Group Limited’s reports filed from time to time
with the Securities and Exchange Commission, including its most recent
Form 20-F and any subsequent filings, available at www.sec.gov.
Readers are urged not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Aptorum does not intend to update any forward-looking statement
contained in this press release to reflect events or circumstances
arising after the date hereof.

This press release does not constitute an offer to sell, or a
solicitation of an offer to buy, any securities, and it does not
constitute an offering prospectus within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Investors must rely on their own evaluation of Aptorum
Group Limited and its securities, including the merits and risks
involved. Nothing contained herein is or shall be relied on as, a
promise or representation as to the future performance of Aptorum Group
Limited.

Contacts

Enquiries:
Investor Contact:
Sabrina Khan, Chief Financial
Officer
Tel: +852 2117 6611
Email: [email protected]

Media Contact:
Tel: + 852 2117 6611
Email: [email protected]